Table 1.

Demographic and clinical characteristics at baseline. Mean values (SD), or mean ± SD, or count (percentage) are shown unless indicated.

CharacteristicAll Patients, n = 100EULAR Responders, n = 50EULAR Nonresponders, n = 50
Age, yrs52 ± 1049 ± 11*56 ± 8*
Female, %878886
Disease duration, yrs5 (2–13)5 (2–10)7 (3–15)
RF-positive, %677262
Erosive disease, %666666
DAS284.7 ± 1.04.9 ± 0.84.6 ± 1.2
ESR, mm/h16 (8–33)15 (8–24)18 (8–39)
CRP, mg/l6 (3–19)6 (3–21)6 (3–17)
HAQ1.1 ± 0.61.1 ± 0.61.1 ± 0.7
Prior DMARD2.9 ± 1.12.8 ± 1.12.9 ± 1.2
MTX use, %798672
MTX dose, mg/wk21.5 ± 6.321.4 ± 5.921.5 ± 6.9
Prednisolone use, %262626
Prednisolone dose, mg/day6.7 ± 4.25.2 ± 3.08.2 ± 4.7
Other DMARD than MTX, %293622
Cardiovascular risk factors
  Body mass index25.5 ± 4.724.9 ± 4.026.1 ± 5.2
  Hypertension, %231422
  Diabetes mellitus, %422
  Current smoking, %262626
  Statin use, %12816
Lipid profile
  Total cholesterol, mmol/l5.0 ± 1.04.9 ± 1.05.0 ± 1.0
  Triglycerides, mmol/l1.3 ± 0.51.2 ± 0.51.3 ± 0.5
  HDL cholesterol, mmol/l1.3 ± 0.51.2 ± 0.41.3 ± 0.5
  LDL cholesterol, mmol/l3.3 ± 0.83.3 ± 0.83.4 ± 0.8
  Total cholesterol/HDL ratio4.4 ± 1.94.4 ± 2.04.4 ± 1.8
  ApoA-I, mg/dl178 ± 36178 ± 33179 ± 39
  ApoA-II, mg/dl30 ± 729 ± 631 ± 8
  ApoB, mg/dl122 ± 31120 ± 33125 ± 29
  ApoE, mg/dl4.4 ± 2.14.7 ± 2.54.1 ± 1.6
  ApoC-III, mg/dl9.9 ± 3.39.3 ± 2.910.6 ± 3.6
  ApoB/ApoA-I ratio0.7 ± 0.30.7 ± 0.30.7 ± 0.3
  • * Patients with European League Against Rheumatism (EULAR) good response were significantly younger than EULAR nonresponders (p < 0.001). IQR: interquartile range; RF: rheumatoid factor; DAS28: Disease Activity Score of 28 joints; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DMARD: disease-modifying antirheumatic drugs; MTX: methotrexate; HAQ: Health Assessment Questionnaire; HDL: high-density lipoprotein; LDL: low-density lipoprotein; apo: apolipoproteins.